Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 151 results for "keshavan"

Luger Shiva Keshavan 15th in Nations Cup, Qualifies for World Cup Finals
NDTV

"Naming a brand like this is more complex than people realise"...

Sujata Keshavan chairperson and executive creative director, Ray+Keshavan We interviewed Sujata Keshavan, chairperson and executive creative director of Ray+Keshavan, the design agency that helped create brand Vistara.. Afaqs, 1 month ago

2 images for "keshavan"

NDTV, 1 month ago
NDTV, 1 month ago
NDTV

Shiva Keshavan makes it 3 out of 3 in Luge World Cup Finals in 2014-15 Season

File Photo of Shiva Keshavan NDTV The final race for India at the International Luge circuit is underway in Altenberg, Germany and it is already the most successful season yet for the country's sole entrant, Shiva Keshavan, who clocked 55.423 ...
 NDTV1 month ago
MedCity News

Janssen regulatory director on CROs: Theyll screw you in a heartbeat

Somecandor fromthedirector of global regulatory affairs at Janssen Research & Development , as she touched on contracting with CROs: Theyll screw you in a heartbeat. Clinical research organizationsare a fine option (and sometimes the only one) ...
 MedCity News3 days ago
MedCity News

Stealth neuroscience startup Ovid Therapeutics raises $5M for… Angelman Syndrome? Stay tuned!

Stealth New York-based startup Ovid Therapeutics just raised $5 million, according to a regulatory filing . CEO Matthew During , an accomplished neuroscientist,declined to comment on the fundraise, though he told me last week that some ...
 MedCity News3 days ago A drug that could raise IQ? Balance Therapeutics raises $18M, conducting Down Syndrome trials  MedCity News1 week ago Antifungals and immunotherapy: Cidara Therapeutics raises $42M Series B  MedCity News1 month ago Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson's drug  MedCity News1 month ago
MedCity News

Biotech is booming for everyone but the employees

Here's some advice: If youre going to work for a biotech, ask for more stock options. TheTimmerman Report is among those who recently put into focus what a few analysts have been saying: Most biotech worker bees aren't seeing the benefits of the ...
 MedCity News4 days ago
MedCity News

T3D Therapeutics exploring the link between diabetes and Alzheimer's disease

There's a growing consensus that two ofsociety's most rampant public health issues Type II Diabetes and Alzheimer's disease are linked . It's not all about clearing plaques anymore:Insulin modulation is askew in both diseases, which has led ...
 MedCity News4 days ago
MedCity News

Startup's device uses targeted radiation brachytherapy to treat macular degeneration

One of the most commonly prescribed drugs for wet age-related macular degeneration is Avastin a cancer drug. So it's not that surprising that a new approach for wet AMD is radiation therapy with aims tohalt the growth of the unruly blood vessels ...
 MedCity News4 days ago
MedCity News

Boston Scientific backs startup's Chronic Veinous Insufficiency treatment in $5.9M Series A

If veins in the legs don't work properly, it can be difficult for blood to return to the heart. Blood can start to pool in the legs and lead to skin changes and painful ulceration.The condition, called chronic vein insufficiency , is actually ...
 MedCity News5 days ago
MedCity News

Emory spinout has topical rosacea therapy in the works

Rosacea is common it impacts 16 million Americans alone but there's no cure for the skin reddening, pimples and bumps characteristic of the disorder. Atlanta startup Accuitis Pharmaceuticals is developing a topical therapy for rosacea. The Emory ...
 MedCity News5 days ago
MedCity News

Why clinical trial recruitment is so hard, and one solution: Patient education

Clinical trials are the lifeblood of the life sciences industry yet less than5 percent of adult cancer patients will pursue experimental therapies.The biggest reason for this? Fear: Although the backbone of today's successful cancer treatments, ...
 MedCity News5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less